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Background and purpose — Perioperative hyperglycemia has 
been associated with adverse outcomes in several fields of sur-
gery. In this observational study, we identified factors associated 
with an increased risk of hyperglycemia following hip and knee 
replacement.
Patients and methods — We prospectively monitored changes 
in glucose following primary hip and knee replacements in 191 
patients with osteoarthritis. Possible associations of patient char-
acteristics and operation-related factors with hyperglycemia 
(defined as glucose > 7.8 mmol/L in 2 consecutive measurements) 
and severe hyperglycemia (glucose > 10 mmol/L) were analyzed 
using binary logistic regression with adjustment for age, sex, 
operated joint, and anesthesiological risk score. 
Results — 76 patients (40%) developed hyperglycemia, and 
48 of them (25% of the whole cohort) had severe hyperglycemia. 
Glycemic responses were similar following hip replacement and 
knee replacement. Previously diagnosed diabetes was associated 
with an increased risk of hyperglycemia and severe hypergly-
cemia, compared to patients with normal glucose metabolism, 
whereas newly diagnosed diabetes and milder glucose metabolism 
disorders had no effect. In patients without previously diagnosed 
diabetes, increased values of preoperative glycosylated hemoglo-
bin (HbA1c) and fasting glucose on the day of operation were 
associated with hyperglycemia. Higher anesthesiological risk 
score—but none of the operation-related factors analyzed—was 
associated with an increased risk of hyperglycemia.
Interpretation — Perioperative hyperglycemia is common in 
primary hip and knee replacements. Previously diagnosed diabe-
tes is the strongest risk factor for hyperglycemia. In patients with 
no history of diabetes, preoperative HbA1c and fasting glucose 
on the day of operation can be used to stratify the risk of hyper-
glycemia.

Stress-induced insulin resistance and consequent periopera-
tive hyperglycemia have been recognized as important risk 
factors for adverse outcomes following major surgical inter-
ventions (Ljungqvist et al. 2007, Akhtar et al. 2010, Rizvi et 
al. 2010). In joint replacements, perioperative hyperglycemia 
is a relatively common phenomenon (Pili-Floury et al. 2009) 
and it has been reported be associated with an increased risk 
of prosthetic joint infection (PJI) (Mraovic et al. 2011) and 
venous thromboembolism (Cohn et al. 2012).
Although there is debate about how intensively periopera-
tive hyperglycemia should be managed (Griesdale et al. 2009), 
it is reasonable to expect that controlling severe hyperglyce-
mia would be beneficial (Ljungqvist et al. 2007, Jämsen et al. 
2010). This is important because, unlike most risk factors for 
PJI (Jämsen et al. 2010, Bozic et al. 2012, Chen et al. 2013), 
hyperglycemia can be modified. Unfortunately, there is little 
information about factors that are predictive of hyperglycemia 
in orthopedic patients. 
Diabetes is a well-established risk factor for PJI (Dowsey 
and Choong 2009, Malinzak et al. 2009, Bozic et al. 2012, 
Jämsen et al. 2012, Chen et al. 2013) and perioperative hyper-
glycemia (Akhtar et al. 2010, Masla et al. 2011, Jämsen et 
al. unpublished data), although it is important to note that 
perioperative hyperglycemia may also develop in the absence 
of an established glucose metabolism disorder (Ljungqvist et 
al. 2007, Donatelli et al. 2008, Gustafsson et al. 2009, Pili-
Floury et al. 2009). Moreover, a considerable proportion of 
patients with type 2 diabetes are undiagnosed (Meding et al. 
2007, Saaristo et al. 2008). Other studies have suggested that 
existing insulin resistance (Donatelli et al. 2007), metabolic 
syndrome (Donatelli et al. 2008), general anesthesia rather 
than epidural (Donatelli et al. 2007), and the severity of tissue 
trauma (Thorell et al. 1999) are associated with perioperative 
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hyperglycemia. However, only 1 of these studies concerned 
joint replacements (Donatelli et al. 2007).
We analyzed the course of perioperative hyperglycemia in 
a series of 191 primary hip and knee replacements performed 
for osteoarthritis, and tried to identify patient characteristics 
and operation-related factors associated with perioperative 
hyperglycemia. We hypothesized that preoperative hypergly-
cemia and greater surgical stress (e.g. duration of surgery and 
amount of tissue trauma) would increase the risk of periopera-
tive hyperglycemia.
Patients and methods
The patients for this prospective observational study were col-
lected at a single publicly funded orthopedic hospital between 
December 2009 and May 2011. Patients of all ages undergo-
ing primary hip or knee replacement for osteoarthritis were 
eligible for inclusion. Patients with and without diabetes were 
included. Exclusion criteria were regular corticosteroid treat-
ment. Based on a previous study (Pili-Floury et al. 2009), it 
was estimated that a convenient sample of 200 operations 
would be sufficient to detect a 1.5-fold difference in the risk 
of hyperglycemia between different patient subgroups (each 
representing ≥ 20% of the material) at the 5% significance 
level with ≥ 80% power. A post-hoc analysis indicated that the 
power calculations allowed 5% loss of study patients.
Study protocol
For the detailed study protocol see Supplementary data. 
Briefly, the patients were recruited after they were scheduled 
for surgery. A research nurse registered their medical history 
and made anthropometric measurements. In addition to rou-
tine preoperative laboratory tests, the patients had their lipid 
values, fasting plasma glucose, and glycosylated hemoglobin 
(HbA1c) measured. Patients with no history of diabetes also 
underwent a 2-h 75-g oral glucose tolerance test, which is 
a commonly used and sensitive means of diagnosing type 2 
diabetes (American Diabetes Association 2013) and other dis-
orders of glucose metabolism (i.e. increased fasting glucose 
(IFG) and impaired glucose tolerance (IGT)). During the hos-
pital stay, glucose was measured 4–6 times a day from capil-
lary blood samples using a bedside glucose monitor (Precision 
Xceed; Abbott Laboratories, Abbott Park, IL), according to a 
predefined scheme. Short-acting insulin (Actrapid; Novo Nor-
disk A/S, Bagsvaerd, Denmark) was administered according 
to the treating anesthesiologist’s instructions to keep glucose 
below 10 mmol/L.
Characteristics of the study population
Of the 200 patients recruited initially, 191 completed the study 
protocol (Figure 1). The patients included were comparable to 
the whole population of osteoarthritis patients treated at our 
hospital during the same period, with respect to age (mean 66 
(43–89) years in the study sample and 69 (18–93) years in all 
other patients; p = 0.002), sex (65% females vs. 63% females, 
respectively; p = 0.6), and operated joint (proportion of knee 
replacements: 61% vs. 57%; p = 0.3).
74 study patients (39%) underwent hip replacement and 117 
study patients (61%) underwent knee replacement. Patient 
demographics, comorbidities, and operative data are presented 
in Table 1. The majority of operations (89%) were unilateral, 
and except for 9 unicompartmental knees, a total joint replace-
ment was implanted. A greater proportion of knee replace-
ment recipients than hip replacement recipients were obese 
(BMI ≥ 30) (56% vs. 38%; p = 0.02), but the prevalences of 
disorders of glucose metabolism, metabolic syndrome, and 
self-reported comorbidities were similar (data not shown). 
Cemented fixation was used in the majority of knee replace-
ments (87 of 117, 74%) whereas 55 of the 74 hip replacements 
(74%) were cementless. Blood loss was greater in hip replace-
ments than in knee replacements (mean 415 (200–3100) mL 
vs. 50 (5–800) mL; p < 0.001), and blood transfusions were 
more common after hip replacement than after knee replace-
ment (22% vs. 6%; p = 0.001).
Operative details
Almost all the patients arrived at the hospital on the day of 
operation. Spinal anesthesia was used in all operations. Intra-
operative fluid replacements were performed using acetated 
Ringer’s solution, which was changed to 5% glucose solu-
tion (to avoid hypoglycemia and catabolic metabolism) after 
surgery and continued until the patient resumed normal food 
intake. A single 3.0-g bolus of cefuroxime was used as anti-
biotic prophylaxis (but when contraindicated, clindamycin 
was used instead). Antibiotic-impregnated cement was used 
in all cemented joint replacements. A pneumatic tourniquet 
Figure 1. Collection of patients.
Patients recruited for this study
n = 200
Patients operated
n = 193
Patients included
n = 191
Hip replacements, 74
Knee replacements, 117
Excluded (n = 7):
– cancelled their consent to participate, 2
– withdrew from surgery, 2
– surgery cancelled due to health-related reasons, 3
Excluded (n = 2):
– inadequate postoperative glucose monitoring, 2
Hip and knee replacements for
osteoarthritis performed between
December 2009 and May 2011
n = 2,756
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was used in all knee replacements. Closed suction drains (if 
used) were removed on the first postoperative day. Subcutane-
ous enoxaparin or oral rivaroxaban was used as thrombopro-
phylaxis. The median length of hospital stay was 4 (1–6) days, 
and approximately two-thirds of the patients were discharged 
to home directly.
Statistics
The primary outcome was occurrence of hyperglycemia 
during the hospitalization. Hyperglycemia was defined as glu-
cose > 7.8 mmol/L in 2 consecutive measurements or glucose 
> 10 mmol/L at any time point. The 7.8 mmol/L cutoff point 
was based on the definition of hyperglycemia by the Ameri-
can Diabetes Association (2013). Glucose > 10 mmol/L (later 
referred to as “severe hyperglycemia”) is considered to be 
the threshold for treating hyperglycemia (American Diabetes 
Association 2013), and it has been associated with postopera-
tive complications in several studies (Akhtar et al. 2010). Thus, 
even a single occurrence of glucose exceeding 10 mmol/L was 
considered to be clinically significant. Occurrence of severe 
hyperglycemia was analyzed as a secondary outcome.
We analyzed possible associations of patient demographics, 
medical history, results of preoperative laboratory tests and 
operation-related data with hyperglycemia. Data related to 
medical history were based on patient reporting. Diagnoses of 
hypertension and (previously diagnosed) diabetes were con-
firmed from patient records and medication data. The Ameri-
can Society of Anesthesiologists (ASA) risk score (Owens et 
al. 1978) was used to assess comorbidity and was analyzed 
as a categorized variable. BMI was analyzed both as a con-
tinuous variable and a categorized variable as follows: normal 
(< 25.0), overweight (25–29.9), obese (30.0–34.9), severely 
obese (35.0–39.9), and morbidly obese (≥ 40.0).
Diabetic status was categorized as follows: normal glucose 
metabolism, IFG and/or IGT, and diabetes (diagnosed either 
previously or using OGTT in this study). HbA1c was cate-
gorized in 3 groups using 6.0% (median value for the whole 
series) and 6.5% (which has been accepted as a means of 
diagnosing diabetes by the American Diabetes Association 
(2013)) as cutoff points. HbA1c was analyzed also as a con-
tinuous variable. Analyses concerning HbA1c, preoperative 
fasting glucose, and baseline glucose (a fasting sample taken 
at the induction of anesthesia) were performed separately for 
patients with and without a previous diagnosis of diabetes. 
Metabolic syndrome was diagnosed according to the consen-
sus criteria (Alberti et al. 2009). Patients whose preoperative 
hemoglobin was below the local laboratory reference values 
(i.e. < 117 g/L in women and < 136 g/L in men) were consid-
ered to have anemia. Renal function was estimated using the 
Cockcroft-Gault formula (Cockcroft and Gault 1976), based 
on preoperative creatitine, and was categorized as normal 
(estimated glomerular filtration rate ≥ 90 mL/min) or as mild 
(60–89 mL/min), moderate (30–59 mL/min), or severe (< 30 
mL/min) renal insufficiency.
Changes in glucose after surgery were similar following hip 
replacement and knee replacement (Figure 2), so the materials 
were analyzed as a whole to maximize statistical power. In 
descriptive analyses, cross-tabulation and the chi-square test 
were used for comparison of categorical variables and inde-
pendent-samples t-test or analysis of variance was used for 
comparison of continuous variables. 
The rates of hyperglycemia and severe hyperglycemia are 
reported as patient numbers and percentages. The associa-
Table 1. Patient demographics, medical status, and operative data
Patient demographics and comorbidity 
Median age at surgery (range), years    66 (43–89)
Sex, no.   
 Female  124 (65%)
 Male    67 (35%)
Median body mass index (range), kg/m2    30 (21–50)
ASA risk score, no.  
 I    16 (8%)
 II    92 (48%)
 III    82 (43%)
 IV      1 (1%)
Self-reported comorbidities, n  
 Hypertension  106 (55%)
 Cardiovascular disease    42 (22%)
 Pulmonary disease    31 (16%)
 Dermatological disease       28 (15%)
 Gastrointestinal disease    22 (12%)
 Genitourinary disease    17 (9%)
 Cancer or history of cancer    14 (7%)
 Neurological disease      6 (3%)
Smoking, n    22 (12%)
Earlier joint replacements, n  
 None  150 (79%)
 Any    41 (21%)
Clinical evaluation in this study  
State of glucose metabolism, n  
 Normal    91 (48%)
 IFG and/or IGT (“pre-diabetes”)    47 (24%)
 Newly diagnosed diabetes    17 (9%)
 Previously diagnosed diabetes    36 (19%)
Metabolic syndrome, n    85 (45%)
Preoperative anemia, n    10 (5%)
Renal function, n a  
 Normal  100 (52%)
 Mild insufficiency    74 (39%)
 Moderate insufficiency    17 (9%)
 Severe insufficiency      0
Operative data   
Simultaneous bilateral surgery, no.    21 (11%)
Total joint replacement, no.  182 (95%)
Prosthesis fixation, no.  
 Cemented  101 (53%)
 Hybrid      7 (4%)
 Cementless    83 (43%)
Median duration of surgery (range), min    85 (44–225)
Median tourniquet time (range), min    50 (0–129)
Median blood loss (range), mL  150 (5–3100)
Blood transfusions, n    24 (13%)
Closed suction drains, n  114 (60%)
a Estimated, based on preoperative creatinine according to the 
Cockcroft-Gault formula.
SD: standard deviation; ASA: American Society of Anesthesiologists; 
IFG: increased fasting glucose; IGT: impaired glucose tolerance.
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tions between potential risk factors for hyperglycemia were 
analyzed using binary logistic regression with adjustment for 
age, sex, operated joint (hip, knee), and ASA risk score. In 
the adjusted analyses, all continuous variables were treated 
as such, i.e. not as categorized. The variables for adjustment 
were selected based on clinical judgment, because they were 
thought to be potentially associated with both intervention 
and development of hyperglycemia. Furthermore, all variables 
were associated with the prevalence of glucose metabolism 
disorders, i.e. the baseline risk of hyperglycemia (data not 
shown). The respective results are presented as adjusted odds 
ratios (ORs) with 95% confidence intervals (CIs). Because 
odds ratios exaggerate the increase in the risk when the initial 
risk is high (over 20–30%) (Davies et al. 1998), we advise the 
reader to look at the actual differences in the occurrence of 
hyperglycemia (i.e. percentages) and to consider the ORs and 
their CIs only as indicators of statistical significance, not as 
indicators of how much the risk is increased. 
Ethics
This study was performed in accordance with the World Medi-
cal Association Declaration of Helsinki. The research plan was 
approved by the Ethics Board of Pirkanmaa Hospital District, 
Tampere, Finland (R09207; November 24, 2009). All patients 
gave informed consent to participate. The study has been reg-
istered at clinicaltrials.gov (NCT01021826).
Results
Altogether, 76 patients (40%) developed hyperglycemia and 
48 of them (25%) had severe hyperglycemia. These propor-
tions were similar in hip and knee replacements (37% vs. 45% 
(p = 0.3) for hyperglycemia and 30% vs. 22% (p = 0.2) for 
severe hyperglycemia, respectively), as was the overall glyce-
mic response to surgery (Figure 2). 
Previously diagnosed diabetes, and increased ASA score, 
preoperative HbA1c, and baseline glucose—but none of the 
operation-related factors analyzed—were associated with 
hyperglycemia and severe hyperglycemia in the adjusted 
analyses (Table 2). The incidence of both hyperglycemia and 
severe hyperglycemia increased with age, but after adjust-
ments there were no statistically significant differences 
between the age groups (Table 2). The effect of ASA score 
(comparing ASA scores III–IV with I–II) was pronounced 
in patients with diabetes (32/38 vs. 7/15; adjusted OR = 6 
(1.3–31)) and in patients with HbA1c ≥ 6.5% (24/25 vs. 3/7; 
adjusted OR = 10 (1.3–82)). ASA score was not associated 
with hyperglycemia in patients without diabetes (adjusted OR 
= 1.4 (0.66–3.4)) and in those with HbA1c < 6.5% (adjusted 
OR = 1.7 (0.66–4.5)).
None of the self-reported comorbidities were associated with 
an increased risk of hyperglycemia (data not shown). Patients 
with a history of other joint replacements (n = 41) had hyper-
glycemia more frequently than those having their first-ever 
joint replacement (n = 150) (56% vs. 35%), but after adjust-
ments there was no statistically significant difference (adjusted 
OR = 1.7 (0.60-4.8)). Smoking had no effect (Table 2).
Diabetes was strongly associated with hyperglycemia 
(Table 2). All 9 patients who were on insulin preoperatively 
presented with severe hyperglycemia during the hospitaliza-
tion, as compared to 19 of 27 of patients treated with oral 
anti-diabetic agents (p = 0.06). Patients with newly diagnosed 
diabetes or prediabetic states (IFG and/or IGT) were similar to 
the patients with normal glucose metabolism in the adjusted 
analyses (Table 2). Metabolic syndrome was associated with 
an increased risk of hyperglycemia and severe hyperglycemia 
(Table 2), but in the absence of co-prevalent diabetes it had 
no effect (13/43 vs. 24/95; adjusted OR = 1.3 (0.61–2.8) for 
hyperglycemia, and 4/43 vs. 13/95; adjusted OR = 0.9 (0.33–
2.6) for severe hyperglycemia). BMI, preoperative anemia, 
and renal function were not associated with perioperative 
hyperglycemia (Table 2).
There was also a strong association between HbA1c and 
both hyperglycemia and severe hyperglycemia, independent 
of diabetic status (Table 3). In particular, 21 of the 22 patients 
with previously diagnosed diabetes and HbA1c ≥ 6.5% were 
hyperglycemic perioperatively and 20 of them developed 
severe hyperglycemia. In patients without previously diag-
nosed diabetes, even slightly increased HbA1c (6.1–6.4%) 
appeared to double the risk of hyperglycemia (Table 3), but 
the difference did not reach statistical significance (adjusted 
OR = 1.7 (0.77–3.9) compared to HbA1c ≤ 6.0%). HbA1c ≥ 
6.5% instead showed a significant effect (adjusted OR = 4.3 
(1.1–17).
Preoperative fasting glucose was not associated with the 
risk of hyperglycemia in patients with or without a previous 
diagnosis of diabetes (adjusted ORs: 1.7 (0.69–4.0) and 1.6 
(0.92–2.7), respectively). Baseline glucose instead increased 
the risk of hyperglycemia in patients without a previous diag-
nosis of diabetes (adjusted OR = 2.4 (1.4–4.3) for an increase 
of 1 mmol/L). Baseline glucose ≥ 7.0 mmol/L in particular, 
compared to ≤ 5.5 mmol/L, markedly increased the odds of 
Figure 2. Mean glucose (with 95% CIs) following primary hip and knee 
replacement in patients with osteoarthritis.
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Table 2. The effects of different patient- and operation-related factors on the incidence of hyperglycemia 
and severe hyperglycemia. The odds ratios (oRs) were adjusted for age, sex, operated joint (hip or knee), 
and the American society of Anesthesiologists risk score
 Hyperglycemia Severe hyperglycemia
    Adjusted   Adjusted
  n n (%) OR (95% CI)  n (%) OR (95% CI)
Gender 
 Male 67 26 (39) 1  17 (25) 1
 Female 124 50 (40) 1.4 (0.70–2.7)  31 (25) 1.3 (0.60–2.6)
Age a   1.0 (0.99–1.1)   1.0 (0.97–1.1)
 < 55 years 20   5 (25) 1    4 (20) 1
 55–64 years 68 20 (29) 0.7 (0.22–2.5)  10 (15) 0.4 (0.11–1.6)
 65–74 years 72 32 (44) 1.0 (0.79–7.3)  20 (28) 0.7 (0.18–2.7)
 ≥ 75 years 31 19 (61) 1.7 (0.42–6.7)  14 (45) 1.2 (0.28–5.5)
ASA risk score 
 I 16   1 (6) 1    1 (6) 1
 II 92 27 (29) 5.0 (0.61–41)  15 (16) 2.6 (0.31–22)
 III 82 48 (59) 15 (1.8–125)  32 (39) 8.0 (0.93–69)
 IV 1   0 (0) -    0 (0) -
Body mass index, kg/m2 a   1.0 (0.94–1.1)   1.0 (0.95–1.1)
 < 25.0 28 12 (43) 1    9 (32) 1
 25.0–29.9 71 27 (38) 1.0 (0.37–2.5)  11 (16) 0.4 (0.14–1.2)
 30.0–34.9 60 24 (40) 1.0 (0.36–2.6)  19 (32) 1.1 (0.39–3.0)
 35.0–39.9 20   8 (40) 1.0 (0.28–3.7)    6 (30) 1.0 (0.26–3.9)
 ≥ 40.0 12   5 (42) 0.8 (0.19–3.8)    3 (25) 0.6 (0.12–3.3)
State of glucose metabolism 
 Normal 91 20 (22) 1  10 (11) 1
 IFG and/or IGT 47 17 (36) 1.8 (0.79–4.1)    7 (15) 1.4 (0.48–4.2)
 Newly diagnosed diabetes 17   8 (47) 2.4 (0.79–7.5)    3 (18) 1.5 (0.34–6.1)
 Previously diagnosed diabetes 36 31 (86) 18 (5.7–59)  28 (78) 29 (9.1–97)
Metabolic syndrome 
 Without 106 31 (29) 1  18 (17) 1
 With 85 45 (53) 2.2 (1.1–4.2)  30 (35) 2.1 (1.03–4.4)
Smoking 
 No 169 67 (40) 1  42 (25) 1
 Yes 22   9 (41) 1.59 (0.52–4.83)    6 (27) 1.6 (0.52–4.8)
Preoperative anemia 
 Without 181 69 (38) 1  44 (24) 1
 With 10   7 (70) 3.9 (0.91–17)    4 (40) 2.0 (0.50–8.1)
Renal function 
 Normal 100 39 (39) 1  26 (26) 1
 Mild insufficiency 74 29 (39) 0.6 (0.28–1.2)  15 (20) 0.5 (0.22–1.2)
 Moderate insufficiency 17   8 (47) 0.5 (0.12–1.6)    7 (41) 1.0 (0.27–3.7)
Operation-related data       
Laterality 
 Unilateral 170 72 (42) 1  45 (27) 1
 Bilateral 21   4 (19) 0.5 (0.14–1.5)    3 (14) 0.7 (0.17–2.5)
Time of induction of anesthesia 
 Before 10 am 95 41 (43) 1  25 (26) 1
 After 10 am 96 35 (37) 0.7 (0.40–1.4)  23 (24) 0.9 (0.43–1.7)
Duration of surgery × 10 min a 191  0.95 (0.86–1.1)   1.03 (0.92–1.2)
Blood loss × 100 mL a 191  1.0 (0.88–1.1)   1.0 (0.90–1.2)
Tourniquet time × 10 min 
 (incl. knees only) a 117  1.0 (0.84–1.2)   1.2 (0.99–1.5)
Cement used for fixation b 
 None 83 36 (43) 1  21 (25) 1
 Any 108 40 (37) 0.8 (0.37–1.6)  27 (25) 1.3 (0.56–2.9)
Blood transfusion 
 None 167 63 (38) 1  38 (23) 1
 Any 24 13 (54) 1.3 (0.48–3.3)  10 (42) 1.8 (0.66–4.7)
Closed suction drains 
 None 77 31 (40) 1  21 (27) 1
 Any 114 45 (40) 2.0 (0.67–5.8)  27 (24) 1.4 (0.44–4.2)
a Continuous 
b Fully cementless vs. fully cemented and hybrid joint replacements.
ASA: American Society of Anesthesiologists; IFG: increased fasting glucose; 
IGT: impaired glucose tolerance. 
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hyperglycemia (adjusted OR = 17 (1.6–178)). In patients with 
a previous diagnosis of diabetes, baseline glucose showed a 
similar, but statistically insignificant association (Table 3). 
Fewer patients undergoing simultaneous bilateral surgery 
than those undergoing unilateral surgery had hyperglycemia 
(4/19 vs. 72/170) but after adjustments, there was no statisti-
cally significant difference (Table 2). None of the 9 patients 
undergoing unicompartmental knee replacement presented 
with hyperglycemia, but 40% of those who received total knee 
replacements did (43 of 108) (p=0.02). The other operation-
related variables available (time of surgery, duration of sur-
gery, tourniquet time, blood loss, use of bone cement for pros-
thesis fixation, use of closed suction drains, allogenous blood 
transfusion) were not associated with occurrence of hypergly-
cemia (Table 2). These results were similar for hip and knee 
replacements, and for unilateral and simultaneous bilateral 
operations (data not shown).
Discussion
One-third of the patients had hyperglycemia following routine 
primary hip or knee replacement for osteoarthritis. In a quarter 
of them, glucose exceeded 10 mmol/L—which is above the 
range recommended for hospitalized patients irrespective of 
their diabetic status (Moghissi et al. 2009, Umpierrez et al. 
2012), and which is also considered the threshold for start-
ing insulin treatment (American Diabetes Association 2013). 
Occurrence of hyperglycemia was strongly related to existing 
disorders of glucose metabolism, particularly to the presence 
of diabetes and to preoperative glucose control, as measured 
by HbA1c. None of the operation-related parameters was 
independently associated with hyperglycemia. 
The main strengths of our study were its prospective nature 
and the study population, which represented the general popu-
lation requiring joint replacement for osteoarthritis well. The 
detailed preoperative evaluation allowed detailed testing of the 
state of preoperative glucose metabolism and other metabolic 
abnormalities. At our institution, perioperative care is highly 
standardized and it remained essentially unchanged during the 
study period. The operations were performed by experienced 
joint replacement surgeons with high numbers of operations 
annually. Thus, differences in the treatment would not bias 
the results much. Furthermore, the coverage of glucose moni-
toring was good—even though ward staff performed it along 
with their daily work.
The key finding was the strong association between exist-
ing disorders of glucose metabolism and perioperative hyper-
glycemia. Our study shows that diabetes, milder disorders 
of glucose metabolism, and metabolic syndrome are very 
common in hip and knee replacement recipients. Given the 
high prevalence of obesity in patients who undergo joint 
replacement surgery (Bourne et al. 2009, Jämsen et al. 2012), 
this is not surprising. One-third of patients with diabetes had 
not been diagnosed prior to scheduling for surgery. However, 
hyperglycemia was less frequent in newly diagnosed diabetes 
patients than in previously diagnosed diabetes patients and, in 
the adjusted analysis, only previously diagnosed diabetes was 
associated with hyperglycemia. 
A clinically important observation in our study was the 
value of HbA1c in stratifying the risk of perioperative hyper-
glycemia, both in patients with and in those without a previous 
diagnosis of diabetes. Almost all patients with diabetes and an 
HbA1c of ≥ 6.5% presented with hyperglycemia. Based on 
our figures, it can be estimated that the incidence of periopera-
tive hyperglycemia could be reduced by almost half if patients 
with diabetes were treated preoperatively to HbA1c ≤ 6.0%. 
To our knowledge, however, there have not been any studies 
that have examined the effectiveness of preoperative glucose 
control in the prevention of perioperative hyperglycemia or 
postoperative complications. Moreover, in a retrospective sin-
gle-center study of 4,241 hip and knee replacements (Iorio et 
al. 2012), HbA1c levels varied markedly in diabetic patients 
both with and without infection, and the average HbA1c was 
not significantly different between these 2 groups. This sug-
gests that, in patients with diabetes, factors other than HbA1c 
also contribute to the occurrence of PJI.
Interestingly, non-diabetic HbA1c values also appeared to 
increase the risk of hyperglycemia in patients with no previ-
ous diagnosis of diabetes (Figure 3). Sato et al. (2010) have 
demonstrated the association between preoperative HbA1c 
and perioperative insulin resistance in cardiac operations, but 
in contrast to our results, such an association was not found 
for patients with no previous diabetes diagnosis. Altogether, 
HbA1c appears to be an easily applicable tool for stratifying 
the risk of perioperative hyperglycemia in joint replacements, 
irrespective of diabetic status. Given the association between 
baseline glucose and hyperglycemia, measuring glucose at 
induction of anesthesia also seems reasonable, but if one relies 
Table 3. Association of preoperative HbA1c and baseline glucose 
(on the day of operation) with occurrence of hyperglycemia in 
patients with and without a previous diagnosis of diabetes 
 Patients with previously Patients without a previous
 diagnosed diabetes diagnosis of diabetes
 Hyper- Hyper-
 glycemia glycemia
 n n (%) p a n n (%) p a
HbA1c      
 ≤ 6.0% 7   4 (57) - 96 20 (21) -
 6.1–6.4% 7   6 (86) 0.3 49 19 (39) 0.01
 ≥ 6.5% 22 21 (95) 0.002 10   6 (60) 0.04
Baseline glucose 
 < 5.6 mmol/L 6   4 (67) - 88 18 (20) -
 5.6–6.9 mmol/L 12 10 (83) 0.4 60 22 (37) 0.03
 > 6.9 mmol/L 18 17 (94) 0.1 5   4 (80) 0.02
a p-values are from pairwise univariate comparisons against the 
lowest HbA1c/glucose category.
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on this measure only, the opportunity to control hyperglyce-
mia preoperatively is lost. 
In addition to markers of disorders of glucose metabo-
lism, the ASA score was associated with an increased risk 
of hyperglycemia. Importantly, the association between 
ASA score and perioperative hyperglycemia was seen 
among patients with diabetes or with a high HbA1c, so dia-
betes as such and glucose control do not explain the result. 
The occurrence of diabetes-related complications (such as 
nephropathy and concomitant cardiovascular disease) might 
be a possible explanation, but this could not be confirmed 
with the present data. 
We hypothesized that operation-related factors such as 
blood loss might be measures of surgical trauma and correlate 
with the hyperglycemic reaction. Contrary to expectations, the 
effects of all the operation-related factors analyzed were slight 
at best and none showed a statistically significant association 
with hyperglycemia. The only exception—and support for our 
hypothesis—was the observation that none of the patients who 
underwent unicondylar knee replacement had hyperglycemia, 
but there were only 9 such patients. Patient selection prob-
ably explains the fact that the occurrence of hyperglycemia 
is lower in bilateral surgery than in unilateral. In our series, 
the operations were highly homogenous, which could explain 
the negative results. In revision joint replacements and trauma 
surgeries (Richards et al. 2012) greater hyperglycemia and 
more variation would be expected.
Compared to an earlier paper reporting on perioperative 
hyperglycemia following hip or knee replacement (Pili-Floury 
et al. 2009), the incidence of perioperative hyperglycemia in 
the present study was much lower, although we also included 
patients with diabetes. In the earlier study, the operations were 
performed under general anesthesia, leading to more diffi-
cult stress-related insulin resistance (Donatelli et al. 2007), 
whereas we used spinal anesthesia. In addition, Pili-Floury 
et al. (2009) had proportionally more postprandial glucose 
measurements than we did. Similarly, in a retrospective study 
in which only fasting samples were analyzed, only 3% of 
patients had glucose levels of > 11.1 mmol/L (> 200 mg/dL) 
(Mraovic et al. 2011). In interpreting our results, it should be 
acknowledged that statistical power was calculated expect-
ing a greater incidence of hyperglycemia. Hence, the lower 
incidence of hyperglycemia (together with the loss of 9 of the 
recruited 200 patients) may have led to false-negative results 
in some comparisons.
It appears likely that the extent of surgical stress-related 
perioperative insulin resistance is smaller in modern hip 
and knee replacements than in, for example, cardiac or open 
abdominal surgery (Thorell et al. 1999, Donatelli et al. 2007). 
The optimal postoperative glucose level in orthopedic sur-
gery is unknown. Although glucose exceeding 7.8 mmol/L is 
considered to be hyperglycemia, recent guidelines (American 
Diabetes Association 2013) and studies in the field of cardio-
thoracic surgery (Bhamidipati et al. 2010) suggest that keep-
ing postoperative glucose levels between 7.8–8.1 and 10.0 
mmol/L may be satisfactory. In fact, control of hyperglycemia 
that is too strict may be harmful—especially in patients with 
severe comorbidities (Griesdale et al. 2009). Thus, the clinical 
significance of hyperglycemia between 7.8 and 10.0 mmol/L, 
as defined in our study, is unclear particularly in patients with-
out diabetes.
Higher glucose values have also been associated with surgi-
cal site infections after orthopedic procedures. In a retrospec-
tive study of 1,948 primary hip or knee replacements, postop-
erative fasting glucose > 200 mg/dL (11.1 mmol/L) doubled 
the risk of PJI (Mraovic et al. 2011). Using the same cutoff 
for glucose, Richards et al. (2012) demonstrated a 3-fold 
risk of surgical site infection following surgical treatment of 
orthopedic trauma. Taking into account that clinical guide-
lines (Moghissi et al. 2009, Umpierrez et al. 2012, American 
Diabetes Association 2013) suggest treatment of hypergly-
cemia > 10.0–11.1 mmol/L, patients with such postoperative 
glucose values—e.g. the patients with severe hyperglycemia 
in our study—should also be identified and treated after joint 
replacement. In addition, it should be acknowledged that 
in these studies as well as in ours, hyperglycemia was first 
treated after it had occurred (insulin was administered on a 
so-called sliding scale basis), which leads to inferior outcomes 
compared to treatment with long-acting basal-bolus insulin 
(Umpierrez et al. 2011). 
In conclusion, postoperative hyperglycemia occurs fre-
quently in primary hip and knee replacement, and in one-
quarter of patients it requires intervention. Most patients with 
previously diagnosed diabetes develop hyperglycemia, which 
is often severe, and they therefore need close glucose monitor-
ing during their hospital stay. In patients with no history of 
diabetes, preoperative HbA1c and fasting glucose on the day 
of surgery can be used to estimate the risk of hyperglycemia.
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